High-Sensitivity C-Reactive Protein and Acute Kidney Injury in Patients with Acute Myocardial Infarction: A Prospective Observational Study by N. Cosentino et al.
Journal of
Clinical Medicine
Article
High-Sensitivity C-Reactive Protein and Acute
Kidney Injury in Patients with Acute Myocardial
Infarction: A Prospective Observational Study
Nicola Cosentino 1, Stefano Genovese 1, Jeness Campodonico 1, Alice Bonomi 1, Claudia Lucci 1,
Valentina Milazzo 1, Marco Moltrasio 1, Maria Luisa Biondi 1, Daniela Riggio 1, Fabrizio Veglia 1,
Roberto Ceriani 1, Katia Celentano 1, Monica De Metrio 1 , Mara Rubino 1,
Antonio L. Bartorelli 1,2 and Giancarlo Marenzi 1,*
1 Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy; nicola.cosentino@ccfm.it (N.C.);
stefano.genovese@ccfm.it (S.G.); jeness.campodonico@ccfm.it (J.C.); alice.bonomi@ccfm.it (A.B.);
claudia.lucci87@gmail.com (C.L.); valentina.milazzo@ccfm.it (V.M.); marco.moltrasio@ccfm.it (M.M.);
maria.biondi@ccfm.it (M.L.B.); daniela.riggio@ccfm.it (D.R.); fabrizio.veglia@ccfm.it (F.V.);
roberto.ceriani@ccfm.it (R.C.); katia.celentano@ccfm.it (K.C.); monica.demetrio@ccfm.it (M.D.M.);
mara.rubino@ccfm.it (M.R.); antonio.bartorelli@ccfm.it (A.L.B.)
2 Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, 20138 Milan, Italy
* Correspondence: giancarlo.marenzi@ccfm.it; Tel.: +39-02-580021; Fax: +39-02-58002287
Received: 11 November 2019; Accepted: 9 December 2019; Published: 12 December 2019 
Abstract: Background. Accumulating evidence suggests that inflammation plays a key role in acute
kidney injury (AKI) pathogenesis. We explored the relationship between high-sensitivity C-reactive
protein (hs-CRP) and AKI in acute myocardial infarction (AMI). Methods. We prospectively included
2,063 AMI patients in whom hs-CRP was measured at admission. AKI incidence and a clinical
composite of in-hospital death, cardiogenic shock, and acute pulmonary edema were the study
endpoints. Results. Two-hundred-thirty-four (11%) patients developed AKI. hs-CRP levels were
higher in AKI patients (45± 87 vs. 16± 41 mg/L; p< 0.0001). The incidence and severity of AKI, as well
as the rate of the composite endpoint, increased in parallel with hs-CRP quartiles (p for trend <0.0001
for all comparisons). A significant correlation was found between hs-CRP and the maximal increase
of serum creatinine (R = 0.23; p < 0.0001). The AUC of hs-CRP for AKI prediction was 0.69 (p < 0.001).
At reclassification analysis, addition of hs-CRP allowed to properly reclassify 14% of patients when
added to creatinine and 8% of patients when added to a clinical model. Conclusions. In AMI,
admission hs-CRP is closely associated with AKI development and severity, and with in-hospital
outcomes. Future research should focus on whether prophylactic renal strategies in patients with
high hs-CRP might prevent AKI and improve outcome.
Keywords: high-sensitivity C-reactive protein; acute kidney injury; acute myocardial infarction;
in-hospital prognosis
1. Introduction
Acute kidney injury (AKI) is a frequent complication of acute myocardial infarction (AMI), and is
associated with an increased risk of prolonged hospital stay, cardiovascular events, renal failure, and
mortality [1,2]. The occurrence of AKI in AMI is a multifactorial event that is promoted by underlying
renal dysfunction, but it is often influenced by multiple contributing factors, such as hemodynamic
impairment and use of contrast agents [3,4]. An early risk stratification for AKI is important because
it might identify high-risk patients who could benefit from preventive measures, such as adequate
hydration and limitation of contrast dose [5,6].
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Acute kidney injury is a complex disorder with a wide variety of etiologies and corresponding risk
factors. The common causes for AKI include renal ischemia/reperfusion injury, systemic inflammatory
processes/sepsis, hemodynamic impairment, and nephrotoxicity [7]. Among them, inflammation
plays a critical role, and several experimental studies have demonstrated an important contribution of
intra-renal and systemic inflammation in promoting parenchymal injury, repair, and fibrosis of the
kidney [8–10]. Growing attention has been focused on C-reactive protein (CRP), a simply detectable
inflammation biomarker, as a possible predictor of AKI and it has been recently recognized that CRP
actively contributes in the pathogenesis and progression of AKI, by exacerbating local inflammation,
impairing the proliferation of damaged tubular epithelial cells, and promoting the fibrosis of injured
renal tissue [11–15]. Moreover, physicians have now become accustomed to use high-sensitivity CRP
(hs-CRP), when considering vascular disease risk stratification, as opposed to the use of standard CRP
assays that monitor infections and other inflammatory conditions [16–18]. In particular, to assess the
cardiovascular risk, CRP should be measured by highly sensitive methods that are capable of reliably
measuring concentrations within the healthy reference interval [16–18].
Emerging evidence showed that serum level of CRP acts as a risk factor and, at the same time, as a
potential causal factor for both AKI development and severity, which is also seen in AMI patients [15].
In coronary artery disease patients, Gao et al. [19], who were the first to perform a retrospective analysis
on 4522 patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting
stents, found that elevated pre-procedural CRP was associated with a progressively increased risk of
contrast-induced AKI. Similarly, a recent retrospective analysis by Han et al. [20], including 1656 patients
undergoing coronary artery bypass grafting, showed that pre-operative CRP level is a predictor of
post-operative AKI. Finally, Shacham et al. prospectively investigated 562 STEMI patients undergoing
primary PCI, and they reported that those with hs-CRP levels >9 mg/L at hospital admission had higher
AKI (17% vs. 6%) and 30-day mortality (11% vs. 1%) rates than patients with hs-CRP levels below this
limit [21]. Thus, it could be hypothesized that, in AMI patients, the association between high levels of
hs-CRP and worse in-hospital prognosis is mediated, at least in part, by AKI occurrence.
In the present study, we prospectively investigated whether hs-CRP levels measured at hospital
admission might predict AKI, as well as its severity, in a large consecutive cohort of AMI patients.
Moreover, we analyzed the possible causal relationship between hs-CRP, AKI, and in-hospital
clinical outcomes.
2. Material and Methods
Study Population. This prospective observational study was conducted at the Centro Cardiologico
Monzino between 1 June 2010 and 31 May 2019. We enrolled all consecutive AMI patients (both STEMI
and non-ST elevation myocardial infarction [NSTEMI] patients) admitted to the Intensive Cardiac
Care Unit (ICCU). We excluded patients in chronic peritoneal or hemodialysis treatment (n = 2), those
with concomitant systemic inflammatory conditions (n = 135) (including active infection [n = 117]) or
malignancies (n = 38), and those who died or underwent emergency cardiac surgery before at least two
consecutive serum creatinine (sCr) values had been collected (n = 34). The Ethics Committee of our
Institute (Centro Cardiologico Monzino) approved the study (study protocol number R520-CCM549),
and written informed consent was obtained from all patients.
Study Protocol. In all patients, hs-CRP was measured at hospital admission through a Cobas®
assay (particle-enhanced immunoturbidimetric assay) on Cobas c501 (Roche) [22]. Serum creatinine
was also measured at hospital admission and daily during ICCU stay. Glomerular filtration rate
(eGFR) was estimated using the Modification of Diet in Renal Disease Study (MDRD) equation [23].
Acute kidney injury was defined applying the Acute Kidney Injury Network classification, according
to the maximum sCr increase recorded between baseline (hospital admission) and the first 72 h [24].
In particular, Stage 1 AKI was defined as a ≥ 0.3 mg/dL sCr increase; Stage 2 as a >2- to 3-fold sCr
increase; Stage 3 as a >3-fold sCr increase or sCr ≥ 4.0 mg/dL with an acute increase >0.5 mg/dL, or
need for renal replacement therapy (RRT), irrespective of the stage at the time of RRT.
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Study patients received standard medical treatment and coronary revascularization (primary
or early PCI in most cases) according to the current standards of care recommended by published
guidelines. Nonionic, low-osmolality contrast agents were used in all patients. In NSTEMI patients,
isotonic (0.9%) saline was administered intravenously at a rate of 1 mL/kg/h for 12 h, before and after
contrast exposure. In STEMI patients, hydration was given for 12 h after PCI. In patients with left
ventricular ejection fraction (LVEF) <40%, or those who showed overt heart failure, the hydration rate
was reduced to 0.5 mL/kg/h.
The primary outcome for this study was the incidence of AKI. A composite of in-hospital mortality,
cardiogenic shock, and acute pulmonary edema was also evaluated as a secondary clinical endpoint
of the study. We used this combined endpoint because cardiogenic shock and acute pulmonary
edema are the complications most closely associated with mortality in AMI, and they are the clinical
manifestations of acute ventricular dysfunction, which is known to be associated with conditions of
acute inflammation [25,26]. Cardiogenic shock was defined as persistent systolic arterial pressure
≤80 mmHg, with evidence of vital organ hypoperfusion caused by severe left ventricular dysfunction,
right ventricular infarction, or mechanical complications of infarction, and not due to hypovolemia,
hemorrhage, bradyarrhythmias, or tachyarrhythmias. Acute pulmonary edema was defined as
respiratory distress, tachypnea, and orthopnea with rales over the lung fields and arterial oxygen
saturation <90%, despite high inspired oxygen concentration. To avoid interference, each patient could
only account for one event classification.
Statistical Analysis. A sample size of 1,060 patients was calculated under the following
assumptions: 10% overall incidence of AKI [2], with an expected 5% and 15% incidence in patients in the
first and last hs-CRP quartiles, respectively. This sample size allowed a 90% statistical power in assessing
a significant difference (α error of 0.0125 considering the Bonferroni correction for 4 comparisons) of the
incidence of AKI between quartiles. This sample (n = 1060) also allowed a 70% statistical power when
an overall incidence of 15% of the combined clinical endpoint was considered [27], with an expected
10% and 20% incidence in patients in the first and last hs-CRP quartiles, respectively. To increase
the statistical power from 70% to 90% regarding the combined clinical endpoint, 2,000 patients were
evaluated, and they represented the final sample size.
Continuous variables are presented as mean ± SD, and they were compared using the t-test for
independent samples. Non-normally distributed variables are presented as median and interquartile
ranges, and they were compared with the Wilcoxon rank-sum test. Categorical data were compared
using the chi-square test or the Fisher exact test, as appropriate. Trends of AKI incidence across hs-CRP
quartiles were assessed by Mantel–Haenszel chi-square.
The identification of independent predictors of AKI in the whole population was assessed by a
logistic regression analysis with the initial set of potential predictors, including variables, found to be
significantly (p < 0.05) associated with AKI, during univariate analysis. Results are presented as odds
ratio (OR) with a 95% confidence intervals (CI).
The receiver operating characteristic (ROC) curves were calculated to measure the ability of the
considered variables to predict AKI. The results are presented as area under the curve (AUC) with 95%
CI. AUC were compared as recommended by DeLong et al. [28]. Net reclassification improvement
(NRI) was used to identify the possible additional prognostic value of hs-CRP when added to admission
sCr and to the variables found to be independently associated with AKI, during multivariate analysis
(age, sCr, LVEF, admission glycemia, and AMI type [STEMI vs. NSTEMI]).
Path analysis using structural equation modeling was also performed in order to explore the
paths through which hs-CRP affects the endpoints [29]. The results of the path analysis are presented
as standardized regression coefficients (β).
All tests were two-tailed, and p < 0.05 was required for statistical significance. All analyses
were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Reclassification statistics were
assessed with the SAS macros published by Cook and Ridker [30].
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3. Results
A total of 2,272 AMI patients were initially enrolled in this study. After screening for eligibility,
2,063 AMI patients (mean age 67 ± 12 years, 73% men, 49% STEMI patients) were included in the final
analysis. Of them, 234 (11%) developed AKI (13% of STEMI and 10% of NSTEMI patients; p = 0.05).
Stage 1 AKI occurred in 173 (8%) patients, and Stage 2–3 AKI occurred in 61 (3%) patients. Thirty-two
AKI patients (2% of the entire population) required RRT.
The baseline clinical characteristics of the patients with and without AKI are shown in Table 1.
Patients with AKI were older and more likely to have co-morbidities, prior cardiovascular events, and
lower eGFR and LVEF. Moreover, AKI patients experienced a higher rate of in-hospital complications,
including mortality (Table 1).
Table 1. Baseline characteristics and in-hospital complications of the study patients according to the
occurrence of acute kidney injury.
Variable
Acute Kidney Injury
No Yes p Value
(n = 1829) (n = 234)
Age (years) 66 ± 12 74 ± 11 <0.0001
Male sex, n (%) 1351 (74%) 165 (71%) 0.27
Body weight (kg) 76 ± 14 76 ± 16 0.88
Diabetes mellitus, n (%) 386 (21%) 87 (37%) <0.0001
Hypertension, n (%) 1157 (63%) 178 (76%) 0.0001
Smokers, n (%) 1003 (55%) 95 (41%) <0.0001
Hyperlipidemia, n (%) 900 (49%) 129 (55%) 0.09
Prior myocardial infarction, n (%) 451 (25%) 82 (35%) 0.0006
Prior CABG, n (%) 210 (11%) 41 (18%) 0.007
Prior PCI, n (%) 450 (25%) 66 (28%) 0.22
Left ventricular ejection fraction (%) 51 ± 11 41 ± 14 <0.0001
STEMI, n (%) 885 (48%) 131 (56%) 0.03
CA/PCI during hospitalization, n (%) 1724 (94%) 206 (88%) 0.0006
Laboratory values at hospital admission
Serum creatinine (mg/dL) 1.0 ± 0.4 1.4 ± 0.9 <0.0001
eGFR (ml/min/1.73m2) 80 ± 26 63 ± 30 <0.0001
Hemoglobin (g/dL) 13.7 ± 1.8 13.1 ± 2.1 <0.0001
Blood glucose (mg/dL) 146 ± 57 192 ± 88 <0.0001
hs-TnI (ng/L) 5223 ± 20,634 12,992 ± 50,065 <0.0001
Medication before hospital admission
Aspirin, n (%) 642 (35%) 108 (46%) 0.0009
Statins, n (%) 601 (33%) 90 (38%) 0.11
Beta-blockers, n (%) 632 (28%) 100 (24%) 0.01
ACE/AR blockers, n (%) 718 (35%) 93 (40%) 0.89
Oral anticoagulants, n (%) 91 (5%) 17 (7%) 0.29
In-hospital complications
In-hospital death, n (%) 9 (0.5%) 30 (13%) <0.0001
Cardiogenic shock, n (%) 58 (3%) 59 (25%) <0.0001
Acute pulmonary edema, n (%) 115 (6%) 99 (42%) <0.0001
Combined clinical endpoint, n (%) 141 (8%) 119 (51%) <0.0001
Mechanical ventilation, n (%) 32 (2%) 46 (20%) <0.0001
Atrial fibrillation, n (%) 147 (8%) 62 (26%) <0.0001
VT/VF, n (%) 127 (7%) 41 (18%) <0.0001
High-degree CD, n (%) 60 (3%) 14 (6%) 0.04
Major bleeding, n (%) 41 (2%) 31 (13%) <0.0001
ICCU length of stay (days) * 4 (3–4) 5 (4–8) <0.001 †
ACE—angiotensin-converting enzyme; AR—angiotensin II receptor; CA—coronary angiography; CABG—coronary
artery bypass graft; CD—conduction disturbances; eGFR—estimated glomerular filtration rate;
hs-TnI—high-sensitivity troponin I; ICCU—intensive cardiac care unit; PCI—percutaneous coronary intervention;
STEMI—ST-segment elevation myocardial infarction; VF—ventricular fibrillation; and VT—ventricular tachycardia.
* Median and interquartile range. † By non-parametric Wilcoxon rank-sum test.
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The mean admission hs-CRP value in the entire population was 19 ± 49 mg/L. Patients who
developed AKI showed markedly higher hs-CRP values than those without AKI (45 ± 87 vs.
16 ± 41 mg/L; p < 0.0001). The incidence of AKI, as well as its severity, increased in parallel
with hs-CRP quartiles (Figure 1). Notably, also when a cut-off value of sCr increase ≥0.5 mg/dL was
considered, AKI incidence significantly increased in parallel with hs-CRP quartiles (3%, 9%, 11%, and
18%, respectively; p for trend <0.0001).
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Figure 1. (A) Acute kidney injury (AKI) rates in the study patients, grouped according to admission
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to its severity in hs-CRP quartiles.
A similar relationship with hs-CRP quartiles was also observed for the incidence of the combined
clinical endpoint (Figure 2).
Moreover, a significant correlation was found between admission hs-CRP values and the
subsequent maximal increase of s r (R = 0.23; p < 0.0001).
Figure 3 shows the OR for AKI, according to hs-CRP quartiles adjusted for baseline clinical
variables that were found to be independently associated with AKI (age, sCr, LVEF, admission glycemia,
and AMI type).
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Figure 3. Adjusted odds ratios (OR) and 95% confidence intervals for acute kidney injury (AKI) risk
according to high-sensitivity C-reactive protein quartiles. Odd ratios were adjusted for baseline clinical
variables found to be independently associated with AKI during multivariate analysis (age, serum
creatinine, left ventricular ejection fraction, admission glycemia, and acute myocardial infarction type).
In the whole population, when hs-CRP was evaluated in terms of its capacity to predict AKI, the
AUC was 0.69 (95% CI 0.65 to 0.73; p < 0.001). Notably, hs-CRP showed a similar capacity to predict
AKI when STEMI (AUC 0.69; 95% CI 0.64 to 0.74; p < 0.001) and NSTEMI (AUC 0.69; 95% CI 0.63 to
0.74; p < 0.001) patients were considered separately. High-sensitivity C-reactive protein significantly
increased the accuracy to predict AKI when added to admission sCr and to the variables found to
ind pendently predict AKI during multivariate analysis. During the reclassification analysis, the
addition of hs- RP to admission sCr allowed to properly reclassify 14% of the patien s. Similarly, when
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hs-CRP was added to the independent clinical variables identified in our cohort, 8% of the patients
were properly reclassified (Table 2).
Table 2. Area under the curve of admission high-sensitivity C reactive protein (hs-CRP) added to
serum creatinine (sCr) and to the clinical variables found to be independently associated with acute
kidney injury, for the prediction of the primary endpoint (acute kidney injury), and reclassification
statistics comparisons.
AUC (95% CI) p ValueAUC
p Value for AUC
Comparison
NRI (95%
CI)
p Value
NRI
Admission sCr 0.66 (0.62–0.70) <0.001 - - -
Admission hs-CRP + sCr 0.72 (0.68–0.76) <0.001 <0.001 14% (10–17) 0.01
Clinical predictors * 0.79 (0.77–0.83) <0.001 - - -
Admission hs-CRP +
clinical predictors * 0.81 (0.78–0.84) <0.001 0.002 8% (3–12) <0.001
AUC—area under the curve; CI—confidence intervals; NRI—net reclassification improvement. *Age, admission
serum creatinine, left ventricular ejection fraction, admission glycemia, and acute myocardial infarction type.
The results of the path analysis with the estimated direct and indirect effects of admission hs-CRP
on AKI and primary endpoint occurrence are presented in Figure 4.
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Figure 4. Sequential path analysis diagram depicting the interrelationships (direct and indirect effects)
between admission high-sensitivity C-reactive protein (hs-CRP), acute kidney injury (AKI), and the
combined clinical endpoint (in-hospital mortality, acute pulmonary edema, and cardiogenic shock).
SE—standard error.
High-sensitivity-CRP was significantly associated with both variables of interest. In particular, it
was associated with the clinical endpoint through both a direct effect (58% of its overall effect) and an
indirect effect (42% of its overall effect), which passed through the development of AKI.
4. Discussion
The major finding of the study was that hs-CRP levels measured at hospital admission in patients
with AMI were independently associated with AKI risk, its sev rity, a d in-hospit l clinical outcomes.
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The development of AKI in AMI patients was strongly associated with a worse prognosis.
Increased in-hospital morbidity and mortality and prolonged hospital stay were reported, along with a
higher risk of progression to end-stage renal disease and subsequent hospitalization for cardiovascular
and renal events [1,2,31]. Thus, AKI prediction is a clinical priority to identify high-risk AMI patients,
in whom preventive strategies should be implemented in order to minimize the risk of AKI and
improve the outcome.
In our study, we prospectively evaluated hs-CRP at hospital admission as a predictor of AKI
in a large consecutive cohort of AMI patients, including both STEMI and NSTEMI. Similar to other
reports [1–4], 11% of our study patients developed AKI. Its occurrence was associated with an in-hospital
mortality strikingly higher than that observed in patients without AKI. Of note, hs-CRP levels were
also significantly higher in patients with AKI than in those without, and it increased in parallel with
increasing AKI severity. At the same time, the risk of AKI increased in parallel with admission hs-CRP
values, while a significant relationship between hs-CRP value and maximal sCr increase was observed
in the entire study population. Remarkably, risk prediction accuracy improved after the addition of
hs-CRP to admission sCr, the most common predictor of AKI in AMI studies, as well as in studies
performed in other clinical settings [32–34]. The accuracy of AKI prediction also improved when
hs-CRP was added to a clinical model including other well-known independent predictors of AKI in
AMI (age, LVEF, sCr, admission glycemia, and AMI type) [33], allowing a reclassification of AKI risk in
nearly 10% of patients.
Given the recognized close association between hs-CRP and in-hospital outcome in AMI [17], we
hypothesized that inflammation might directly contribute to acute organ injury and, in turn, affect
patient prognosis. Indeed, higher admission levels of hs-CRP in AMI have been reported to predict
left ventricular dysfunction [35] and heart failure [36], suggesting that inflammatory processes play
an independent role in cardiac function impairment during AMI. To better elucidate this point, in
addition to AKI, we considered a combined clinical endpoint including acute pulmonary edema,
cardiogenic shock, and death, which are clinical equivalents of acute ventricular dysfunction. Our
findings seem to confirm such a hypothesis, suggesting that high levels of hs-CRP are closely associated
with an increased risk of AKI and, at the same time, with a worse in-hospital prognosis. This is further
supported by the results of the path analysis, demonstrating that the association between hs-CRP and
in-hospital outcome is the result of both a direct effect (58% of the hs-CRP overall effect) and an indirect
effect, which passes through the development of AKI (42% of its overall effect).
The mechanisms underlying the association between hs-CRP and AKI risk remain uncertain
and they require further exploration. However, based on our results and on those of the existing
literature, there is compelling evidence that elevation of hs-CRP level in AMI patients might not
just be a marker of inflammation, it might also directly contribute to the inflammatory state causing
injury to different organs, and particularly to kidney and heart, whose dysfunctions are the most
important variables associated with AMI prognosis [37–39]. Indeed, hs-CRP has been demonstrated to
reduce nitric oxide production and to impair antioxidant defenses, resulting in endothelial dysfunction
and decreased activity of renal vasodilators, both major contributors to AKI development [11,14,40].
At the same time, in conditions characterized by acute and systemic inflammation, such as severe
burn, trauma, or sepsis, a decrease in cardiac myocyte contractility often occurs. The mechanisms of
myocardial dysfunction are related with the inflammatory response mediated by cytokines, oxidative
stress, endothelial dysfunction, and mitochondrial abnormalities. In particular, cytokines act as the
most important mediators of the inflammatory process. Tumor necrosis factor-α, interleukin-1β, and
interleukin-6 are increased during an inflammatory response, and they have been shown to have a
negative inotropic effect on cardiomyocyte contractility and, at the same time, to cause acute renal
dysfunction [25,26].
Our findings might have some relevant clinical implications. Previous meta-analyses and
studies demonstrated that the administration of statins significantly reduces AKI incidence, as
well as myocardial infarct size, in AMI patients [41,42]. As statins are known to have pleiotropic
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and anti-inflammatory effects, the early administration of high-dose statins might blunt the acute
inflammatory response in AMI and exert renal-protective and cardio-protective effects. Moreover,
hs-CRP measurement in the first hours of hospital admission could be utilized easily to identify
high-risk AMI patients in whom early prophylactic strategies aimed at preventing AKI or at reducing
its severity, like furosemide-induced diuresis with matched hydration, should be implemented [6].
The strengths of our study include a well-characterized AMI population, the adjustment for
several risk factors, a special focus on the relationship between hs-CRP and AKI, and the use of an
innovative statistical methodology (path analysis) that is able to elucidate the possible causal pathways
between hs-CRP and the outcomes of interest. However, some limitations of the study should be
mentioned. First, we included a population admitted to a single center. Second, sCr at hospital
admission may not represent a true baseline renal function in AMI patients because AKI could have
already occurred due to hemodynamic impairment, potentially underestimating AKI incidence and
severity. Thus, our data cannot ascertain whether hs-CRP is a predictor or an early marker of AKI.
Nevertheless, our path analysis might suggest a causal link between admission hs-CRP and AKI.
Third, we did not serially evaluate hs-CRP in our patients. Notably, it has been recently reported that
changes in hs-CRP over time, rather than a single value measured at hospital admission, are more
accurate predictors of AKI in STEMI patients undergoing primary PCI [43]. It is also possible that
other inflammation indices that we have not considered, such as the CRP to albumin ratio, might be
more accurate in predicting AKI in AMI patients [44]. Finally, clinical events were assessed during
hospital stay only, precluding to draw any inference from our data regarding long-term outcomes.
5. Conclusions
In conclusion, in patients hospitalized with AMI, hs-CRP measured at admission is closely
associated with AKI development and severity. Future research should focus on whether targeted
prophylactic renal strategies in high-risk patients, selected according to hs-CRP value, might prevent
AKI and improve clinical outcome.
Author Contributions: N.C., G.M. and A.L.B. had full access to all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis; Study concept and design: G.M., N.C., S.G.
and A.L.B.; Acquisition of data: J.C., C.L., V.M., M.M., M.L.B., D.R., R.C., K.C., M.D.M. and M.R.; Analysis and
interpretation of data: G.M., N.C., S.G. and A.L.B.; Drafting the manuscript: N.C., G.M., S.G., J.C. and A.L.B.;
Critical revision of the manuscript for important intellectual content: A.B.; Statistical analysis: A.B. and F.V.;
Obtained funding: G.M.; Administrative, technical, or material support: G.M.; Study supervision: N.C., G.M.
and A.L.B.
Funding: Funding/support: This work was supported by the Centro Cardiologico Monzino, Institute of Cardiology,
University of Milan, Italy. Role of the sponsor: The study’s sponsor had no role in the design and in conducting
the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of
the manuscript.
Acknowledgments: We acknowledge Michela Palmieri, for her precious help in revising the manuscript.
Conflicts of Interest: We have no conflicts of interest to disclose, including specific financial interests and
relationships and affiliations relevant to the subject of this manuscript.
References
1. Marenzi, G.; Cosentino, N.; Bartorelli, A.L. Acute kidney injury in patients with acute coronary syndromes.
Heart 2015, 101, 1778–1785. [CrossRef] [PubMed]
2. Marenzi, G.; Cabiati, A.; Bertoli, S.V.; Assanelli, E.; Marana, I.; De Metrio, M.; Rubino, M.; Moltrasio, M.;
Grazi, M.; Campodonico, J.; et al. Incidence and relevance of acute kidney injury in patients hospitalized
with acute coronary syndromes. Am. J. Cardiol. 2013, 111, 816–822. [CrossRef] [PubMed]
3. Marenzi, G.; Lauri, G.; Assanelli, E.; Campodonico, J.; De Metrio, M.; Marana, I.; Grazi, M.; Veglia, F.;
Bartorelli, A.L. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute
myocardial infarction. J. Am. Coll Cardiol. 2004, 44, 1780–1785. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 2192 10 of 12
4. Marenzi, G.; Assanelli, E.; Campodonico, J.; Lauri, G.; Marana, I.; De Metrio, M.; Moltrasio, M.; Grazi, M.;
Rubino, M.; Veglia, F.; et al. Contrast volume during primary percutaneous coronary intervention and
subsequent contrast-induced nephropathy and mortality. Ann. Intern. Med. 2009, 150, 170–177. [CrossRef]
[PubMed]
5. Kaltsas, E.; Chalikias, G.; Tziakas, D. The Incidence and the prognostic impact of acute kidney injury in
acute myocardial infarction patients: Current preventive strategies. Cardiovasc. Drugs Ther. 2018, 32, 81–98.
[CrossRef]
6. Marenzi, G.; Ferrari, C.; Marana, I.; Assanelli, E.; De Metrio, M.; Teruzzi, G.; Veglia, F.; Fabbiocchi, F.;
Montorsi, P.; Bartorelli, A.L. Prevention of contrast nephropathy by furosemide with matched hydration:
The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast
Induced Nephropathy Prevention) trial. JACC Cardiovasc. Interv. 2012, 5, 90–97. [CrossRef]
7. Levey, A.S.; James, M.T. Acute kidney injury. Ann. Intern. Med. 2017, 167, ITC66–ITC80. [CrossRef]
8. Rabb, H.; Griffin, M.D.; McKay, D.B.; Swaminathan, S.; Pickkers, P.; Rosner, M.H.; Kellum, J.A.; Ronco, C.
Acute Dialysis Quality Initiative Consensus XIII Work Group. Inflammation in AKI: Current understanding,
key questions, and knowledge gaps. J. Am. Soc. Nephrol. 2016, 27, 371–379. [CrossRef]
9. Glodowski, S.D.; Wagener, G. New insights into the mechanisms of acute kidney injury in the Intensive Care
Unit. J. Clin. Anesth. 2015, 27, 175–180. [CrossRef]
10. Andrade-Oliveira, V.; Foresto-Neto, O.; Watanabe, I.K.M.; Zatz, R.; Câmara, N.O.S. Inflammation in Renal
Diseases: New and Old Players. Front. Pharmacol. 2019, 10, 1192. [CrossRef]
11. McFadyen, J.D.; Kiefer, J.; Braig, D.; Loseff-Silver, J.; Potempa, L.A.; Eisenhardt, S.U.; Peter, K. Dissociation of
C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of C-reactive
protein and its conformational changes. Front. Immunol. 2018, 9, 1351. [CrossRef] [PubMed]
12. Vigushin, D.M.; Pepys, M.B.; Hawkins, P.N. Metabolic and scintigraphic studies of radioiodinated human
C-reactive protein in health and disease. J. Clin. Investig. 1993, 91, 1351–1357. [CrossRef] [PubMed]
13. Lai, W.; Tang, Y.; Huang, X.R.; Tang, P.M.K.; Xu, A.; Szalai, A.J.; Lou, T.Q.; Lan, H.Y. C-reactive protein
promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E. Kidney Int. 2016, 90, 610–626.
[CrossRef] [PubMed]
14. Sproston, N.R.; Ashworth, J.J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol.
2018, 9, 754. [CrossRef] [PubMed]
15. Tang, Y.; Mak, S.K.; Lan, H.Y. Role of C-reactive protein in the pathogenesis of acute kidney injury. Nephrology
2018, 23 (Suppl. 4), 50–52. [CrossRef] [PubMed]
16. Rifai, N.; Ballantyne, C.M.; Cushman, M.; Levy, D.; Myers, G.L. Point: High-sensitivity C-reactive protein
and cardiac C-reactive protein assays: Is there a need to differentiate? Clin. Chem. 2006, 52, 1254–1256.
[CrossRef]
17. Crea, F.; Libby, P. Acute coronary syndromes: The way forward from mechanisms to precision treatment.
Circulation 2017, 136, 1155–1166. [CrossRef]
18. Yousuf, O.; Mohanty, B.D.; Martin, S.S.; Joshi, P.H.; Blaha, M.J.; Nasir, K.; Blumenthal, R.S.; Budoff, M.J.
High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J. Am.
Coll. Cardiol. 2013, 62, 397–408. [CrossRef]
19. Gao, F.; Zhou, Y.J.; Zhu, X.; Wang, Z.J.; Yang, S.W.; Shen, H. C-reactive protein and the risk of contrast-induced
acute kidney injury in patients undergoing percutaneous coronary intervention. Am. J. Nephrol. 2011, 34,
203–210. [CrossRef]
20. Han, S.S.; Kim, D.K.; Kim, S.; Chin, H.J.; Chae, D.W.; Na, K.Y. C-reactive protein predicts acute kidney injury
and death after coronary artery bypass grafting. Ann. Thorac. Surg. 2017, 104, 804–810. [CrossRef]
21. Shacham, Y.; Leshem-Rubinow, E.; Steinvil, A.; Keren, G.; Roth, A.; Arbel, Y. High sensitive C-reactive protein
and the risk of acute kidney injury among ST-elevation myocardial infarction patients undergoing primary
percutaneous intervention. Clin. Exp. Nephrol. 2015, 19, 838–843. [CrossRef] [PubMed]
22. Podmore, C.; Meidtner, K.; Schulze, M.B.; Scott, R.A.; Ramond, A.; Butterworth, A.S.; Di Angelantonio, E.;
Danesh, J.; Arriola, L.; Barricarte, A.; et al. The association of multiple biomarkers of iron metabolism and
type 2 diabetes - the EPIC-InterAct Study. Diabetes Care 2016, 39, 572–581. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 2192 11 of 12
23. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. Modification of Diet in Renal Disease
Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new
prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130,
461–470. [CrossRef] [PubMed]
24. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute Kidney
Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11, R31.
[CrossRef] [PubMed]
25. Rudiger, A.; Singer, M. The heart in sepsis: From basic mechanisms to clinical management. Curr. Vasc.
Pharmacol. 2013, 11, 187–195. [PubMed]
26. Takasu, O.; Gaut, J.P.; Watanabe, E.; To, K.; Fagley, R.E.; Sato, B.; Jarman, S.; Efimov, I.R.; Janks, D.L.;
Srivastava, A.; et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am. J. Respir.
Crit. Care Med. 2013, 187, 509–517. [CrossRef]
27. Marenzi, G.; Cosentino, N.; Boeddinghaus, J.; Trinei, M.; Giorgio, M.; Milazzo, V.; Moltrasio, M.; Cardinale, D.;
Sandri, M.T.; Veglia, F.; et al. Diagnostic and prognostic utility of circulating cytochrome c in acute myocardial
infarction. Circ. Res. 2016, 119, 1339–1346. [CrossRef]
28. DeLong, E.R.; DeLong, D.M.; Clarke-Pearson, D.L. Comparing the areas under two or more correlated
receiver operating characteristic curves: A nonparametric approach. Biometrics 1988, 44, 837–845. [CrossRef]
29. Stein, C.M.; Morris, N.J.; Hall, N.B.; Nock, N.L. Structural equation modeling. Methods Mol. Biol. 2017, 1666,
557–580.
30. Cook, N.R.; Ridker, P.M. Advances in measuring the effect of individual predictors of cardiovascular risk:
The role of reclassification measures. Ann. Intern. Med. 2009, 150, 795–802. [CrossRef]
31. James, M.T.; Ghali, W.A.; Knudtson, M.L.; Ravani, P.; Tonelli, M.; Faris, P.; Pannu, N.; Manns, B.J.;
Klarenbach, S.W.; Hemmelgarn, B.R. Alberta Provincial Project for Outcome Assessment in Coronary Heart
Disease (APPROACH) Investigators. Associations between acute kidney injury and cardiovascular and
renal outcomes after coronary angiography. Circulation 2011, 123, 409–416. [CrossRef] [PubMed]
32. Marenzi, G.; Cosentino, N.; Milazzo, V.; De Metrio, M.; Rubino, M.; Campodonico, J.; Moltrasio, M.; Marana, I.;
Grazi, M.; Lauri, G.; et al. Acute kidney injury in diabetic patients with acute myocardial infarction: Role of
acute and chronic glycemia. J. Am. Heart Assoc. 2018, 7, e008122. [CrossRef] [PubMed]
33. Marenzi, G.; Cosentino, N.; Moltrasio, M.; Rubino, M.; Crimi, G.; Buratti, S.; Grazi, M.; Milazzo, V.;
Somaschini, A.; Camporotondo, R.; et al. Acute kidney injury definition and in-hospital mortality in patients
undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
J. Am. Heart Assoc. 2016, 5, e003522. [CrossRef] [PubMed]
34. Cardinale, D.; Cosentino, N.; Moltrasio, M.; Sandri, M.T.; Petrella, F.; Colombo, A.; Bacchiani, G.; Tessitore, A.;
Bonomi, A.; Veglia, F.; et al. Acute kidney injury after lung cancer surgery: Incidence and clinical relevance,
predictors, and role of N-terminal pro B-type natriuretic peptide. Lung Cancer 2018, 123, 155–159. [CrossRef]
35. Ammirati, E.; Cannistraci, C.V.; Cristell, N.A.; Vecchio, V.; Palini, A.G.; Tornvall, P.; Paganoni, A.M.;
Miendlarzewska, E.A.; Sangalli, L.M.; Monello, A.; et al. Identification and predictive value of interleukin-6+
interleukin-10+ and interleukin-6− interleukin-10+ cytokine patterns in ST-elevation acute myocardial
infarction. Circ. Res. 2012, 111, 1336–1348. [CrossRef]
36. Stumpf, C.; Sheriff, A.; Zimmermann, S.; Schaefauer, L.; Schlundt, C.; Raaz, D.; Garlichs, C.D.; Achenbach, S.
C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation
myocardial infarction treated with coronary angioplasty. Arch. Med. Sci. 2017, 13, 1086–1093. [CrossRef]
37. Halkin, A.; Stone, G.W.; Dixon, S.R.; Grines, C.L.; Tcheng, J.E.; Cox, D.A.; Garcia, E.; Brodie, B.; Stuckey, T.D.;
Mehran, R.; et al. Impact and determinants of left ventricular function in patients undergoing primary
percutaneous coronary intervention in acute myocardial infarction. Am. J. Cardiol. 2005, 96, 325–331.
[CrossRef]
38. Gibson, C.M.; Pinto, D.S.; Murphy, S.A.; Morrow, D.A.; Hobbach, H.P.; Wiviott, S.D.; Giugliano, R.P.;
Cannon, C.P.; Antman, E.M.; Braunwald, E.; et al. TIMI Study Group Association of creatinine and creatinine
clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol.
2003, 42, 1535–1543. [CrossRef]
39. Marenzi, G.; Moltrasio, M.; Assanelli, E.; Lauri, G.; Marana, I.; Grazi, M.; Rubino, M.; De Metrio, M.; Veglia, F.;
Bartorelli, A.L. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients
with acute myocardial infarction undergoing primary angioplasty. Am. Heart J. 2007, 153, 755–762. [CrossRef]
J. Clin. Med. 2019, 8, 2192 12 of 12
40. Fujii, H.; Li, S.H.; Szmitko, P.E.; Fedak, P.W.; Verma, S. C-reactive protein alters antioxidant defenses and
promotes apoptosis in endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2476–2482.
[CrossRef]
41. Marenzi, G.; Cosentino, N.; Cortinovis, S.; Milazzo, V.; Rubino, M.; Cabiati, A.; De Metrio, M.; Moltrasio, M.;
Lauri, G.; Campodonico, J.; et al. Myocardial infarct size in patients on long-term statin therapy undergoing
primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am. J. Cardiol. 2015,
116, 1791–1797. [CrossRef]
42. Marenzi, G.; Cosentino, N.; Werba, J.P.; Tedesco, C.C.; Veglia, F.; Bartorelli, A.L. A meta-analysis of randomized
controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and
without acute coronary syndromes. Int. J. Cardiol. 2015, 183, 47–53. [CrossRef]
43. Zahler, D.; Rozenfeld, K.L.; Stein, M.; Milwidsky, A.; Berliner, S.; Banai, S.; Arbel, Y.; Shacham, Y. C-reactive
protein velocity and the risk of acute kidney injury among ST-elevation myocardial infarction patients
undergoing primary percutaneous intervention. J. Nephrol. 2019, 32, 437–443. [CrossRef] [PubMed]
44. Karabag˘, Y.; Çag˘das¸, M.; Rencuzogullari, I.; Karakoyun, S.; Artaç, I˙.; I˙lis¸, D.; Yesin, M.; Çiftçi, H.; Erdog˘du, H.I.;
Tanbog˘a, I.H. Protein to albumin ratio predicts acute kidney injury in patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous coronary intervention. Heart Lung Circ. 2018, 28,
1638–1645. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
